Clinical Trial Update: A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) [Phase 1]

View source ↗

Summary

Merck completed a Phase 1 study (MK-6024-015) evaluating efinopegdutide in healthy obese participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Efinopegdutide (efinopegdutide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Healthy | Phase 1 | Status: COMPLETED